Multiple-variable dose regimen for treating TNFα-related disorders

  • US 8,961,974 B2
  • Filed: 03/28/2014
  • Issued: 02/24/2015
  • Est. Priority Date: 04/09/2004
  • Status: Active Grant
First Claim
Patent Images

1. A multiple-variable dose method for treating ulcerative colitis in a subject in need thereof, comprising subcutaneously administering to the subject:

  • a first dose of 160 mg of a recombinant human anti-TNFα

    antibody administered to the subject within a day; and

    a second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;

    wherein the antibody comprises;

    a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    8;

    a CDR2 comprising the amino acid sequence of SEQ ID NO;

    6; and

    a CDR3 comprising the amino acid sequence of SEQ ID NO;

    4; and

    a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;

    7;

    a CDR2 comprising the amino acid sequence of SEQ ID NO;

    5; and

    a CDR3 comprising the amino acid sequence of SEQ ID NO;

    3.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×